Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Day 28 MRD-negative complete remission rates were significantly lower in patients who received >=2 cycles versus 1 cycle of bridging chemotherapy (56% versus 94%, p=0.017).

Effect: decline; 56% vs 94%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

There was no difference in incidence of cytokine release syndrome (p>0.99) or neurotoxicity/ICANS (p=0.70) between patients who received >=2 cycles versus 1 cycle of bridging chemotherapy.

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null